

ASX Announcement

3 July 2026

Cleansing notice under section 708A(5)(e) of the Corporations Act

This notice is being given by Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**). The Company has today issued the remaining placement shares totalling 150,000 fully paid ordinary shares (**Shares**) at an issue price of \$0.40 per Share to sophisticated investors. These Shares represent the balance of the capital raising under the placement announced to the market on 26 June 2026. The Appendix 2A relating to the issue of these Shares has been released to ASX prior to this announcement.

For the purposes of section 708A(6) of the Corporations Act, the Company advises that:

- (a) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - ii. sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act, which is required to be disclosed by the Company.

For further information, please contact:

Maggie Niewidok
Company Secretary
company.secretary@recce.com.au

This announcement has been approved for release by Recce Pharmaceuticals Board.



ASX: RCE, FSE: R9Q

Head Office: Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 T +61 (2) 9000 1907

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA